105 research outputs found
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
Rivaroxaban and other oral direct factor Xa inhibitors (ODiXa) are currently developed for prophylaxis and treatment of thromboembolic diseases using fixed doses. Although routine monitoring is not required, assessing the intensity of anticoagulation may be useful under certain clinical conditions. ODiXa prolong coagulation times of several clotting assays and, thus, their concentration may be determined in factor Xa specific chromogenic substrate assays. So far, no standardized and validated assay is commercially available. Here, five methods (A through E) are studied and optimized to reduce interassay variability. Human pooled plasma was spiked by a serial dilution of rivaroxaban (25–900 ng/ml). The release of para-nitroaniline from the chromogenic substrates was measured by the optical density (OD) at 405 nm. Method B was identified to yield the lowest sum of deviations from the mean value of the OD concentration curve calculated from all assays. Spline functions were developed for OD versus concentration curves for all methods. The calculated OD versus concentration curves overlapped for all methods. The coefficient of variation for all assays and concentrations of rivaroxaban decreased from 25.3 ± 11.4% using the original data to 3.8 ± 2.2% using the calculated data (P < 0.0001). The robustness of the chromogenic assay (method B) remains to be corroborated in interlaboratory comparisons
Using trendsetting chefs to design new culinary preparations with the "Penjar" tomato
New food products are normally marketed after research regarding consumers' preferences. As an alternative, we used trendsetting chefs to develop and evaluate products with the traditional, long shelf life,Postprint (published version
Delayed Stellar Mass Assembly in the Low Surface Brightness Dwarf Galaxy KDG215
We present HI spectral line and optical broadband images of the nearby low
surface brightness dwarf galaxy KDG215. The HI images, acquired with the Karl
G. Jansky Very Large Array (VLA), reveal a dispersion dominated ISM with only
weak signatures of coherent rotation. The HI gas reaches a peak mass surface
density of 6 M pc at the location of the peak surface
brightness in the optical and the UV. Although KDG215 is gas-rich, the
H non-detection implies a very low current massive star formation rate.
In order to investigate the recent evolution of this system, we have derived
the recent and lifetime star formation histories from archival Hubble Space
Telescope images. The recent star formation history shows a peak star formation
rate 1 Gyr ago, followed by a decreasing star formation rate to the
present day quiescent state. The cumulative star formation history indicates
that a significant fraction of the stellar mass assembly in KDG215 has occurred
within the last 1.25 Gyr. KDG215 is one of only a few known galaxies which
demonstrates such a delayed star formation history. While the ancient stellar
population (predominantly red giants) is prominent, the look-back time by which
50% of the mass of all stars ever formed had been created is among the youngest
of any known galaxy.Comment: Accepted for publication in the Astrophysical Journal Letter
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
Many drugs have been reported to cause thrombotic microangiopathy (TMA), yet evidence supporting a direct association is often weak. In particular, TMA has been reported in association with recombinant type I interferon (IFN) therapies, with recent concern regarding the use of IFN in multiple sclerosis patients. However, a causal association has yet to be demonstrated. Here, we adopt a combined clinical and experimental approach to provide evidence of such an association between type I IFN and TMA. We show that the clinical phenotype of cases referred to a national center is uniformly consistent with a direct dose-dependent drug-induced TMA. We then show that dose-dependent microvascular disease is seen in a transgenic mouse model of IFN toxicity. This includes specific microvascular pathological changes seen in patient biopsies and is dependent on transcriptional activation of the IFN response through the type I interferon α/β receptor (IFNAR). Together our clinical and experimental findings provide evidence of a causal link between type I IFN and TMA. As such, recombinant type I IFN therapies should be stopped at the earliest stage in patients who develop this complication, with implications for risk mitigation
TRAIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism.
DNA lesions encountered by replicative polymerases threaten genome stability and cell cycle progression. Here we report the identification of mutations in TRAIP, encoding an E3 RING ubiquitin ligase, in patients with microcephalic primordial dwarfism. We establish that TRAIP relocalizes to sites of DNA damage, where it is required for optimal phosphorylation of H2AX and RPA2 during S-phase in response to ultraviolet (UV) irradiation, as well as fork progression through UV-induced DNA lesions. TRAIP is necessary for efficient cell cycle progression and mutations in TRAIP therefore limit cellular proliferation, providing a potential mechanism for microcephaly and dwarfism phenotypes. Human genetics thus identifies TRAIP as a component of the DNA damage response to replication-blocking DNA lesions.This work was supported by funding from the Medical Research Council and the European Research Council (ERC, 281847) (A.P.J.), the Lister Institute for Preventative Medicine (A.P.J. and G.S.S.), Medical Research Scotland (L.S.B.), German Federal Ministry of Education and Research (BMBF, 01GM1404) and E-RARE network EuroMicro (B.W), Wellcome Trust (M. Hurles), CMMC (P.N.), Cancer Research UK (C17183/A13030) (G.S.S. and M.R.H), Swiss National Science Foundation (P2ZHP3_158709) (O.M.), AIRC (12710) and ERC/EU FP7 (CIG_303806) (S.S.), Cancer Research UK (C6/A11224) and ERC/EU FP7 (HEALTH-F2- 2010-259893) (A.N.B. and S.P.J.).This is the author accepted manuscript. The final version is available from NPG via http://dx.doi.org/10.1038/ng.345
- …